As its Phase III tesmilifene trial continues to enroll breast cancer patients, YM BioSciences Inc. entered a bought-deal agreement that could result in gross proceeds for the company of C$23 million (US$17.8 million). (BioWorld Today)
Chiron Corp. finalized a settlement agreement with F. Hoffmann-La Roche Ltd. concerning an HIV patent late last week, then announced Monday an agreement to provide InterMune Inc. with its hepatitis C targets. (BioWorld Today)
Less than two months after filing a new drug application for Tarceva to treat non-small-cell lung cancer, Genentech Inc. and OSI Pharmaceuticals Inc. started a Phase IIIb study of the drug. (BioWorld Today)
Entering the first major pharmaceutical deal for its Fragments of Active Structures drug discovery technology, Structural GenomiX formed an alliance with F. Hoffmann-La Roche Ltd. to discover new antiviral therapeutics. (BioWorld Today)
MGI Pharma Inc.'s stock surged nearly 20 percent Wednesday after it announced a marketing deal for SuperGen Inc.'s Dacogen, as well as its plans to acquire two private companies focused on oncology. (BioWorld Today)
